Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9423366 | 0.98 | KMO (0.46) | KMOALOX15TSHRHIF1AHCAR2 | |
| SCHEMBL3685745 | 0.86 | ALOX15 (0.54) | KMOALOX15TSHRHIF1AHCAR2 | |
| SCHEMBL27410251 | 0.81 | LMNA (0.47) | TSHRLMNA | |
| SCHEMBL1760306 | 0.80 | KMO (0.49) | KMOALOX15TSHRHIF1AHCAR2 | |
| SCHEMBL7070167 | 0.78 | KMO (0.30) | KMO | |
| SCHEMBL3808604 | 0.78 | KDM4E (0.42) | TDP1LMNAKDM4EMAPTALDH1A1 | |
| SCHEMBL14609864 | 0.78 | BAZ2B (0.44) | RAB9A | |
| Orotic Acid SCHEMBL185887 | 0.77 | ALOX15 (0.50) | ALOX15TSHRHIF1AHCAR2DAO | |
| SCHEMBL9196203 | 0.77 | KMO (0.54) | KMOALOX15TSHRHIF1AHCAR2 | |
| SCHEMBL125608 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4339193-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2024-03-20 | — | — | EP | disclosed |
| CN-113330009-B | Azacyclic compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022237858-A1 | COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-115340528-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| CN-113330009-A | Nitrogen heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| WO-2020182018-A1 | NITROGEN HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020182018-A1 | NITROGEN HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-09-17 | — | — | WO | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| CN-101910184-A | Solubility thiazole and pyridine | SIRTRIS PHARMACEUTICALS INC | 2010-12-08 | — | — | CN | disclosed |
| CN-101827845-A | Cgrp antagonists | BOEHRINGER INGELHEIM INT | 2010-09-08 | — | — | CN | disclosed |
| EP-2217606-A1 | SOLUBILIZED THIAZOLOPYRIDINES | Sirtris Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2205599-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| EP-2205590-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061453-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009050234-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | KMO 634/4885ALOX15 1795/4885TSHR 1088/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | KMO 3996/4885ALOX15 2368/4885TSHR 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.